Fundz

Watching RAPHAEL PHARMACEUTICAL INC.? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Executive ChangeItem 5.02 · 8-KMEDIUM RiskNeutral

RAPHAEL PHARMACEUTICAL INC.

raphaelpharmaceutical.com
Filed: Jul 16, 2026CIK: 0001415397Health Care
Full company profileView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Raphael Pharmaceutical Inc. announced the appointment of Uri Tadelis as Chief Financial Officer effective July 16, 2026, following the immediate resignation of Guy Ofir from the CFO, General Counsel, and Director positions. The company stated the departure was not due to disagreements, indicating a planned management transition.

Key Takeaways

Guy Ofir resigned from three positions (CFO, General Counsel, Director) effective immediately on July 16, 2026

Uri Tadelis was appointed as the new Chief Financial Officer on the same date

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJul 16, 2026
Item5.02
CategoryExecutive Change
CIK0001415397
Accession #0001415397
Risk LevelMEDIUM
SentimentNeutral
Signalinformational
Topics
leadership transitionexecutive departureexecutive hire

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings

RAPHAEL PHARMACEUTICAL INC. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.